GILEAD SCIENCES, INC. (GILD)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$7,628.0M
Cash & Equivalents
$2,544.0M
Quarterly Burn Rate
$161,193M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
EFAVIRENZ, EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE
ATRIPLA |
NDA | Absence of Signs or Symptoms, Acceptability of Health Care, Acquired Immune Deficiency Syndrome, Acquired Immune Deficiency Syndrome (AIDS), Acquired Immunodeficiency Syndrome, Acute Coronary Syndrome, Acute Hepatitis C, Acute HIV Infection, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Addiction, Adherence to Medication Regime, Adherence, Medication, Adherence, Patient, Adherence, Treatment, Adolescent Behavior, Advanced Breast Cancer, Advanced Estrogen Receptor Positive HER2- Breast Cancer, Advanced HR+/HER2- Breast Cancer, Advanced Illness, Advanced Microsatellite Stable Colorectal Cancer, Advanced Non-Small Cell Lung Cancer, Advanced or Metastatic Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumor, Advanced Solid Tumor, Advanced Solid Tumors, Advanced Upper Gastrointestinal Tract Adenocarcinoma, Ageing, Aggressive NHL, Aging, Biological, Aicardi Goutières Syndrome, AIDS, AIDS and Infect |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-27 | Pdufa | — |
| 2026-08-28 | Phase3 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
| 2026-12-23 | Pdufa | — |
| 2027-06-01 | Phase3 Readout | — |
Active Clinical Trials (13)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03577197 | Southeast Netherlands Advanced Metastatic Breast Cancer Registry | OTHER | Recruiting | 7,000 |
| NCT07476339 | REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE | PHASE4 | Recruiting | 200 |
| NCT03275311 | Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 | OTHER | Recruiting | 42,000 |
| NCT07210125 | Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting | PHASE4 | Active Not Recruiting | 75 |
| NCT06964113 | A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine ... | PHASE4 | Active Not Recruiting | 94 |
| NCT05814432 | Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS | PHASE3 | Recruiting | 279 |
| NCT06413498 | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multip... | PHASE3 | Active Not Recruiting | 452 |
| NCT05633654 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Neg... | PHASE3 | Recruiting | 1,514 |
| NCT04986579 | Scalp Cooling in MBC | PHASE2 | Recruiting | 120 |
| NCT05396885 | Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | PHASE2 | Active Not Recruiting | 136 |
| NCT06631365 | PrEPsmart 2-1-1 Pilot | PHASE2 | Recruiting | 60 |
| NCT05833867 | Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer | PHASE1 | Recruiting | 20 |
| NCT04155749 | Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma | PHASE1 | Active Not Recruiting | 40 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.